A Health Canada spokesperson told Global News in an email on Wednesday evening that the agency was aware of the recent FDA alert and was actively monitoring safety information received from multiple sources, including international regulators. As of July 29, 2024, Health Canada has not received adverse reaction reports relating to dosing errors in which it is specified that the suspect product is a compounded injectable semaglutide product, spokesperson Mark Johnson said
References: Waltz Health Launches New Direct-to-Employer Access Model for Obesity Management Medications Lilly, Novo Nordisk back direct-to-employer programs to expand access to weight-loss drugs Obesity and Severe Obesity Prevalence in Adults: United States, August 2021August 2023 FDA Approves Treatment for Serious Liver Disease Known as MASH Tirzepatide as Compared with Semaglutide for the Treatment of Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Direct medical costs of obesity in the United States and the most populous states
Sonderpreisen, die exklusiv ber Dritte ausgelobt werden
Among 142,349 participants with type 2 diabetes or obesity in the All of Us Research Program, we assessed co-occurrence across four SUD phenotypesAUD, CUD, OUD, and NUD
